MedTrace Logo

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT05732831 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2026-04-21

No results posted yet for this study

Summary

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Conditions

  • Locally Advanced Solid Tumor

Interventions

DRUG

TNG462

TNG462, a selective PRMT5 inhibitor, will be administered orally

DRUG

Pembrolizumab

An anti PD-1 antibody, will be administered intravenously

Sponsors & Collaborators

  • Tango Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Maxim Pimpkin, MD · Tango Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-26
Primary Completion
2026-05-31
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05732831 on ClinicalTrials.gov